Literature DB >> 16175613

Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine.

Helen H Wang1, David Q-H Wang.   

Abstract

It has been found that polymorphisms in the apolipoprotein (APO)-B gene are associated with cholesterol gallstones in humans. We hypothesized that APO-B plays a major regulatory role in the response of biliary cholesterol secretion to high dietary cholesterol and contributes to cholesterol gallstone formation. In the present study, we investigated whether lack of expression of intestinal Apob48 or Apob100 reduces susceptibility to cholesterol gallstones by decreasing intestinal absorption and biliary secretion of cholesterol in male mice homozygous for an "APO-B48 only" allele (Apob(48/48)), an "APO-B100 only" allele (Apob(100/100)), or a wild-type APO-B allele (Apob+/+) before and during an 8-week lithogenic diet. We found that cholesterol absorption was significantly decreased as a result of the APO-B48 deficiency in Apob(100/100) mice compared with wild-type and Apob(48/48) mice, regardless of whether chow or the lithogenic diet was administered. Consequently, hepatic cholesterol synthesis was significantly increased in Apob(100/100) mice compared with wild-type and Apob(48/48) mice. On chow, the APO-B100 deficiency in Apob(48/48) mice with reduced plasma levels of LDL/VLDL--but not HDL cholesterol--induced relative hyposecretion of biliary bile salts and phospholipids accompanying normal biliary cholesterol secretion. Compared with Apob(48/48) and wild-type mice, lithogenic diet-fed Apob(100/100) mice displayed significantly lower secretion rates of biliary cholesterol, but not phospholipid or bile salts, which results in significant decreases in prevalence rates, numbers, and sizes of gallstones. In conclusion, absence of expression of intestinal Apob48, but not Apob100, reduces biliary cholesterol secretion and cholelithogenesis, possibly by decreasing intestinal absorption and hepatic bioavailability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16175613     DOI: 10.1002/hep.20867

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

1.  Transgenic overexpression of Abcb11 enhances biliary bile salt outputs, but does not affect cholesterol cholelithogenesis in mice.

Authors:  Helen H Wang; Frank Lammert; Anne Schmitz; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2010-04-28       Impact factor: 4.686

2.  XbaI polymorphisms of apolipoprotein B gene: another risk factor of gallstone formation after radical gastrectomy.

Authors:  Feng-Lin Liu; Wen-Bin Lu; Wei-Xin Niu
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

Review 3.  Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.

Authors:  Helen H Wang; Piero Portincasa; Ornella de Bari; Kristina J Liu; Gabriella Garruti; Brent A Neuschwander-Tetri; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2013-02-19       Impact factor: 4.686

Review 4.  Mouse models of gallstone disease.

Authors:  Tony Y Wang; Piero Portincasa; Min Liu; Patrick Tso; David Q-H Wang
Journal:  Curr Opin Gastroenterol       Date:  2018-03       Impact factor: 3.287

5.  Decreased expression of cholesterol 7alpha-hydroxylase and altered bile acid metabolism in Apobec-1-/- mice lead to increased gallstone susceptibility.

Authors:  Yan Xie; Valerie Blanc; Thomas A Kerr; Susan Kennedy; Jianyang Luo; Elizabeth P Newberry; Nicholas O Davidson
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

6.  Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.

Authors:  Helen H Wang; Piero Portincasa; Nahum Mendez-Sanchez; Misael Uribe; David Q-H Wang
Journal:  Gastroenterology       Date:  2008-03-10       Impact factor: 22.682

7.  Prevention of gallbladder hypomotility via FATP2 inhibition protects from lithogenic diet-induced cholelithiasis.

Authors:  Kevin M Tharp; Amin Khalifeh-Soltani; Hyo Min Park; David A Yurek; Alaric Falcon; Louis Wong; Rouying Feng; Kamran Atabai; Andreas Stahl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-31       Impact factor: 4.052

8.  Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters.

Authors:  Mark A Valasek; Joyce J Repa; Gang Quan; John M Dietschy; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-08-21       Impact factor: 4.052

9.  Therapy of gallstone disease: What it was, what it is, what it will be.

Authors:  Piero Portincasa; Agostino Di Ciaula; Leonilde Bonfrate; David Qh Wang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06

10.  Roles of ApoB-100 gene polymorphisms and the risks of gallstones and gallbladder cancer: a meta-analysis.

Authors:  Yi Gong; Leida Zhang; Ping Bie; Huaizhi Wang
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.